摘要
结直肠癌的发生是一个多基因、多步骤的过程。许多已知基因(结肠腺瘤样息肉基因、磷脂酰肌醇-3-激酶基因、肉瘤基因、P53基因等)的突变都是通过微小RNA-135b(miR-135b)起作用。miR-135b能够通过调控基因的活性,参与许多基因的转录。抑制miR-135b的表达可以同时阻断多个致癌基因的突变,有望成为不引起耐药的抗癌新途径。在血液样本及粪便中筛查miR-135b,有望成为结直肠癌早期筛查的新方法。
Colorectal cancer has a muhigenic and muhistep pathogenic process. Genic mutations of adenomatous polyposis coli, phosphoinositide-3-kinases, sarcoma gene and P53 mediated by microRNA-135b participate in the pathogenesis and development of colorectal cancer. MicroRNA-135b is invo.lved in multiple signals of gene activity and transcription. Inhibition on microR-135b expression may be a novel anticancer approach. Detection of microRNA-135b in blood and fecal specimen can be a new method for early screening of colorectal cancer.
作者
路丽娟
刘明浩
刘建军
王瑞玲
Lu Lijuan, Liu Minghao, Liu Jianjun, Wang Ruiling(Department of Gastroenterology, the Second Artillery Force General Hospital of People＇s Liberation Army, Beijing 100088, Chin)
出处
《中国医药》
2018年第3期477-480,共4页
China Medicine
